Conor wins favourable UK ruling in Angiotech paclitaxel dispute
This article was originally published in Clinica
Executive Summary
Conor Medsystems saw its shares hitting an all-time high last week after a UK court verdict rendered a paclitaxel patent held by the firm's legal adversary Angiotech Pharmaceuticals invalid. The ruling, handed down on February 24, comes just a week after Conor CE-marked its cobalt chromium, paclitaxel-eluting CoStar stent (see Clinica No 1195, p 3).